South African Thoracic Society position statement on asthma in children, adolescents and adults
Article Sidebar
Main Article Content
Abstract
It is estimated that 10% of the global population has asthma. Low- and middle-income countries typically struggle to provide affordable asthma care, including access to combination (inhaled corticosteroid (ICS)-long-acting beta-2-agonist) inhalers currently recommended internationally as standard of care. In South Africa (SA), a study found higher asthma prevalence among children in affluent areas compared with those from less affluent backgrounds. Asthma mortality is increasing in Africa and Southeast Asia compared with declines in high-income countries. This mortality crisis stems from inadequate care strategies, reliance on reliever therapy, and patient non- adherence. Overuse of and over-reliance on short-acting beta-2-agonist (SABA) inhalers worsen outcomes, with severe morbidity related to asthma. Limited access to and use of ICS-based controller therapy worsen outcomes. The carbon footprint of inhalers and proposed changes in propellants to those with lower global warming potential due to be phased in by 2030 may further limit treatment availability in the near future. To combat these challenges, the SA Asthma Action Group has been formed, bringing together healthcare professionals, funders and government representatives to improve asthma management. The strategic plan of this group is to address SABA overuse, contribute to guidelines, and enhance accessibility to essential medications while engaging with pharmaceutical companies to ensure affordable access to high-quality asthma treatments.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication.
How to Cite
References
1. Mphahlele R, Lesosky M, Masekela R. Prevalence, severity and risk factors for asthma in school-going adolescents in KwaZulu Natal, South Africa. BMJ Open Respir Res 2023;10(1):e001498. https://doi.org/10.1136/bmjresp-2022-001498
2. Baard CB, Franckling-Smith Z, Munro J, Workman L, Zar HJ. Asthma in South African adolescents: A time trend and risk factor analysis over two decades. ERJ Open Res 2021;7(2):00576-2020. https://doi.org/10.1183/23120541.00576-2020
3. Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross- sectional study. Lancet 2021;398(10311):1569-1580. https://doi.org/10.1016/S0140- 6736(21)01450-1
4. García-Marcos L, Asher MI, Pearce N, et al. The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study. Eur Respir J 2022;60(3):2102866. https://doi.org/10.1183/13993003.02866-2021
5. Mortimer K, Lesosky M, García-Marcos L, et al. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur Respir J 2022;60(3):2102865. https://doi.org/10.1183/13993003.02865-2021
6. García-Marcos L, Chiang CY, Asher MI, et al. Asthma management and control in children, adolescents, and adults in 25 countries: A Global Asthma Network Phase I cross-sectional study. Lancet Glob Health 2023;11(2):e218-e228. https://doi. org/10.1016/S2214-109X(22)00506-X
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. https://ginasthma.org/wp-content/uploads/2017/02/wmsGINA-2017- main-report-final_V2.pdf (accessed 17 September 2025).
8. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev 2021, Issue 5. Art. No.: CD013518. https://doi. org/10.1002/14651858.CD013518.pub2
9. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. JAMA 2018;319(14):1485-1496. https://doi.org/10.1001/jama.2018.2769
10. Lalloo UG, Kalla IS, Abdool-Gaffar S, et al. Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update. Afr J Thorac Crit Care Med 2021;27(4):10.7196/AJTCCM.2021. v27i4.189. https://doi.org/10.7196/AJTCCM.2021.v27i4.189
11. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial. Lancet Respir Med 2013;1(1):32-42. https://doi.org/10.1016/S2213-2600(13)70007-9
12. Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol 2014;134(6):1260-1268.e3. https://doi.org/10.1016/j.jaci.2014.05.041
13. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide- formoterol as needed in mild asthma. N Engl J Med 2018;378(20):1865-1876. https:// doi.org/10.1056/NEJMoa1715274
14. Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018;378(20):1877- 1887. https://doi.org/10.1056/NEJMoa1715275
15. Reddel HK, O’Byrne PM, FitzGerald JM, et al. Efficacy and safety of as-needed budesonide-formoterol in adolescents with mild asthma. J Allergy Clin Immunol Pract 2021;9(8):3069-3077.e6. https://doi.org/10.1016/j.jaip.2021.04.016
16. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): A 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394(10202):919-928. https:// doi.org/10.1016/S0140-6736(19)31948-8
17. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380(21):2020-2030. https://doi. org/10.1056/NEJMoa1901963
18. Green R, Davis G, Price D. Perceptions, impact and management of asthma in South Africa: A patient questionnaire study. Prim Care Respir J 2008;17(4):212-216. https:// doi.org/10.3132/pcrj.2008.00027
19. Smith C, Ambaram A, Mitha E, et al. Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study. Afr J Thorac Crit Care Med 2022;28(4):172-180. https://doi.org/10.7196/AJTCCM.2022.v28i4.220
20. BahadoriK,Doyle-WatersMM,MarraC,etal.Economicburdenofasthma:Asystematic review. BMC Pulm Med 2009;9:24. https://doi.org/10.1186/1471-2466-9-24
21. Global Asthma Network. The Global Asthma Report 2018. September 2018. https:// www.globalasthmareport.org/2018/resources/Global_Asthma_Report_2018.pdf (accessed 17 September 2025).
22. Stanciole AE, Ortegón M, Chisholm D, Lauer JA. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: Mathematical modelling study. BMJ 2012;344:e608. https://doi. org/10.1136/bmj.e608
23. Stolbrink M, Thomson H, Hadfield RM, et al. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: A systematic review. Lancet Glob Health 2022;10(10):e1423-e1442. https:// doi.org/10.1016/S2214-109X(22)00330-8
24. Ozoh OB, Eze JN, Garba BI, et al. Nationwide survey of the availability and affordability of asthma and COPD medicines in Nigeria. Trop Med Int Health 2021;26(1):54-65. https://doi.org/10.1111/tmi.13497
25. Kibirige D, Kampiire L, Atuhe D, et al. Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: The Ugandan perspective. BMC Pulm Med 2017;17(1):179. https://doi.org/10.1186/s12890-017-0527-y
26. Stolbrink M, Ozoh OB, Halpin DMG, et al. Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: A cross-sectional study. Thorax 2024;79(7):676-679. https://doi.org/10.1136/ thorax-2023-221349
27. Pritchard JN. The climate is changing for metered-dose inhalers and action is needed. Drug Des Devel Ther 2020;14:3043-3055. https://doi.org/10.2147/DDDT.S262141
28. Zare Jeddi M, Soltanmohammadi R, Barbieri G, et al. To which extent are per-and
poly-fluorinated substances associated to metabolic syndrome? Rev Environ Health
2021;37(2):211-228. https://doi.org/10.1515/reveh-2020-0144
29. Woodcock A, Beeh KM, Sagara H, et al. The environmental impact of inhaled therapy:
Making informed treatment choices. Eur Respir J 2022;60(1):2102106. https://doi.
org/10.1183/13993003.02106-2021
30. Kponee-Shovein K, Marvel J, Ishikawa R, et al. Carbon footprint and associated costs of asthma exacerbation care among UK adults. J Med Econ 2022;25(1):524-531. https:// doi.org/10.1080/13696998.2022.2063603
31. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2023. https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full- Report-2023-WMS.pdf (accessed 17 September 2025).
32. Li X, Cao X, Guo M, Xie M, Liu X. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: Systematic analysis for the Global Burden of Disease Study 2017. BMJ 2020;368:m234. https://doi. org/10.1136/bmj.m234
33. Adeleye BN. Income inequality, human capital and institutional quality in sub-Saharan Africa. Soc Indic Res 2024;171(1):133-157. https://doi.org/10.1007/s11205-023-03244-0 34. World Health Organization. The Global Health Observatory. Geneva: WHO, 2017. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
(accessed 15 September 2025).
35. O’ByrneP,FabbriLM,PavordID,PapiA,PetruzzelliS,LangeP.Asthmaprogressionand
mortality: The role of inhaled corticosteroids. Eur Respir J 2019;54(1):1900491. https://
doi.org/10.1183/13993003.00491-2019
36. Hasford J, Virchow JC. Excess mortality in patients with asthma on long-acting beta2- agonists. Eur Respir J 2006;28(5):900-902. https://doi.org/10.1183/09031936.00085606 37. Patel M, Pilcher J, Hancox RJ, et al. The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: A post-hoc analysis. NPJ Prim Care Respir
Med 2015;25:14099. https://doi.org/10.1038/npjpcrm.2014.99
38. Stolbrink M, Chinouya MJ, Jayasooriya S, et al. Improving access to affordable quality-
assured inhaled medicines in low- and middle-income countries. Int J Tuberc Lung Dis
2022;26(11):1023-1032. https://doi.org/10.5588/ijtld.22.0270
39. Jayasooriya S, Stolbrink M, Khoo EM, et al. Clinical standards for the diagnosis and
management of asthma in low- and middle-income countries. Int J Tuberc Lung Dis
2023;27(9):658-667. https://doi.org/10.5588/ijtld.23.0203
40. Forum of International Respiratory Societies.On World Asthma Day respiratory health
associations call for asthma care for all. 26 April 2023. https://firsnet.org/on-world- asthma-day-respiratory-health-associations-call-for-asthma-care-for-all/ (accessed 13 September 2025).